Response to "Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries".
A recent supplement article by Talbird, Taylor, Knoll, Frostad, and García Martí reported estimates of public health impact and cost-effectiveness of the 10-valent pneumococcal conjugate vaccine compared with the 7-valent vaccine. Although the analysis applies a decision analytic model and modeling methodologies that are scientifically sound, many of the assumptions presented in the paper are inconsistent with the current evidence.